Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064103 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT00064103: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00064103 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00064103, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best dose of gene therapy and to see how well it works in preventing cancer in patients with premalignant carcinoma of the oral cavity or pharynx. Inserting the p53 gene into a person's tumor cells may improve the body's ability to kill the tumor cells
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL Ad5CMV-p53 gene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2003-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064103
The ClinicalTrials.gov registry entry for NCT00064103 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00064103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064103 about?
NCT00064103 is a clinical study titled "Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx". This phase I/II trial is studying the side effects and best dose of gene therapy and to see how well it works in preventing cancer in patients with premalignant carcinoma of the oral cavity or pharynx. Inserting the p53 gene into a person's tumor cells may improve the body's ability to kill the tumo...
What is the current status of trial NCT00064103?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2003-06.
What interventions are being tested in trial NCT00064103?
The interventions under investigation include: laboratory biomarker analysis (OTHER), Ad5CMV-p53 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00064103?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.